Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 8/2013

01-12-2013 | Research Paper

Electrochemotherapy is effective in the treatment of rat bone metastases

Authors: Milena Fini, Francesca Salamanna, Annapaola Parrilli, Lucia Martini, Matteo Cadossi, Melania Maglio, Veronica Borsari

Published in: Clinical & Experimental Metastasis | Issue 8/2013

Login to get access

Abstract

Bone metastases impair general health status, quality of life and survival of patients. Electrochemotherapy (ECT), which combines electroporation (EP) and the administration of anticancer drugs, has been recently introduced into clinical practice for the local treatment of solid tumours. In the present study, the ability of EP with bleomycin (Bleo) to induce MRMT-1 rat breast cancer cell death was investigated in vitro. Then, an in vivo model for bone metastases was set up by the inoculation of MRMT-1 cells in rat proximal tibia. 7 days after tumour induction the animals were treated with Bleo, EP, Bleo followed by EP (ECT), or left untreated. ECT eliminated the tumour in 6 out of 8 (75 %) treated metastases. Radiological evaluation showed that the Honore score in ECT-treated animals was significantly lower when compared with the other groups (p < 0.0005) and not significantly different from healthy controls. Bone morphology in ECT-treated animals, evaluated by histological and microtomographical analyses, showed intact cortical and trabecular bone structure with new bone apposition. Histomorphometric evaluation showed that ECT-treated metastases had significantly higher bone volume, trabecular number, trabecular thickness and bone mineral density compared with those of untreated metastases (respectively p < 0.0005 for BV/TV, Tb.N and BMD; p < 0.05 for Tb.Th) or metastases treated with Bleo (p < 0.05 for BV/TV, Tb.N, p < 0.005 for BMD) or EP (p < 0.005 for BV/TV, Tb.N; p < 0.0005 for BMD). These findings suggest that early ECT treatment of bone metastases is minimally invasive, safe and effective, thus providing pre-clinical evidence for its use in the treatment of human bone metastases.
Literature
1.
2.
Gissel H, Lee RC, Gehl J (2011) Electroporation and cellular physiology. In: Kee ST, Gehl J, Lee EW (eds) Clinical Aspects of Electroporation. Springer, New York, pp 9–17CrossRef
3.
Orlowski S, Belehradek J Jr, Paoletti C, Mir LM (1988) Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 37(24):4727–4733PubMedCrossRef
4.
Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J Jr, Mir LM (1999) Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 57(1):45–56. doi:10.​1016/​S0006-2952(98)00282-2 PubMedCrossRef
5.
6.
Silve A, Mir LM (2011) Cell electropermeabilization and cellular uptake of small molecules: the electrochemotherapy concept. In: Kee ST, Gehl J, Lee EW (eds) Clinical aspects of electroporation. Springer, New York, pp 69–82CrossRef
7.
Spugnini EP, Dotsinsky I, Mudrov N, Citro G, D’Avino A, Baldi A (2008) Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumour model of chemoresistance: sticker sarcoma. J Exp Clin Cancer Res 27:58. doi:10.​1186/​1756-9966-27-58 PubMedCrossRef
8.
9.
10.
11.
Sersa G, Cemazar M, Miklavcic D, Chaplin DJ (1999) Tumour blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 19:4017–4022PubMed
12.
13.
Engstrom PE, Ivarsson K, Tranberg KG, Stenram U, Salford LG, Persson BR (2001) Electrically mediated drug delivery for treatment of an adenocarcinoma transplanted into rat liver. Anticancer Res 21:1817–1822PubMed
14.
Mitsui K, Kato K, Nakamura K, Yamada Y, Honda N, Fukatsu H, Yoshikawa K (2002) Effective treatment of bladder tumour-bearing mice by direct delivery of bleomycin using electrochemotherapy. Drug Deliv 9:249–252. doi:10.​1080/​1071754026039786​4 PubMedCrossRef
15.
Miyazaki S, Gunji Y, Matsubara H, Shimada H, Uesato M, Suzuki T, Kouzu T, Ochiai T (2003) Possible involvement of antitumour immunity in the eradication of colon 26 induced by low-voltage electrochemotherapy with bleomycin. Surg Today 33:39–44. doi:10.​1007/​s005950300006 PubMedCrossRef
16.
Zheng MH, Feng B, Li JW, Lu AG, Wang ML, Hu WG, Ma JJ, Yu BM (2005) Effects and possible anti-tumour immunity of electrochemotherapy with bleomycin on human colon cancer xenografts in nude mice. World J Gastroenterol 11:2426–2430PubMed
17.
Kitamura A (2003) Bleomycin-mediated electrochemotherapy in mouse NR-S1 carcinoma. Cancer Chemother Pharmacol 51:359–362PubMed
18.
Ivanov MA, Lamrihi B, Szyf M, Scherman D, Bigey P (2003) Enhanced antitumour activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. J Gene Med 5:893–899PubMedCrossRef
19.
Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, Morrissey A, Dunne C, O’Sullivan GC (2006) Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett 232(2):300–310. doi:10.​1016/​j.​canlet.​2005.​03.​057 PubMedCrossRef
20.
21.
22.
Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billarda V, Geertsenc PF, Larkind JO, Miklavcice D, Pavlovice I, Paulin-Kosirb SM, Cemazarb M, Morslia N, Sodend DM, Rudolfb Z, Roberta C, O’Sullivand GC, Mir LM (2006) Electrochemotherapy: an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4:3–13. doi:10.​1016/​j.​ejcsup.​2006.​08.​002 CrossRef
23.
24.
25.
26.
Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek J Jr, Bachaud JM, DeConti R, Stabuc B, Cemazar M, Coninx P, Heller R (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77:2336–2342. doi:10.​1038/​bjc.​1998.​388 PubMedCrossRef
27.
28.
29.
Shimizu T, Nikaido T, Gomyo H, Yoshimura Y, Horiuchi A, Isobe K, Ebara S, Takaoka K (2003) Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 8:248–251PubMedCrossRef
30.
31.
32.
Richetta AG, Curatolo P, D’Epiro S, Mancini M, Mattozzi C, Giancristoforo S, Rotunno R, Calvieri S (2011) Efficacy of electrochemotherapy in ulcerated basal cell carcinoma. Clin Ter 162:443–445PubMed
33.
Marenco F, Nardò T, Savoia P, Bernengo MG (2011) Effectiveness of electrochemotherapy in treatment of a recurrent squamous cell carcinoma of the scalp. Eur J Dermatol 21:618–619PubMed
34.
35.
Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010) Electrochemotherapy for cutaneous and subcutaneous tumour lesions: a novel therapeutic approach. Dermatol Ther 23:651–661. doi:10.​1111/​j.​1529-8019.​2010.​01370.​x PubMedCrossRef
36.
37.
38.
39.
40.
Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW (2000) Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Nat Neurosci 98:585–595. doi:10.​1016/​S0306-4522(00)00110-X
41.
Otsu N (1979) Threshold selection method from grey level histograms. IEEE Trans Syst Man Cybern SMC 9:62–66CrossRef
42.
43.
44.
Hildebrand T, Ruegsegger P (1997) A new method for the model independent assessment of thickness in three dimensionel images. J Microsc 185:67–75CrossRef
45.
46.
47.
48.
49.
Ehrenfeld GM, Rodriguez LO, Hecht SM, Chang C, Basus VJ, Oppenheimer NJ (1985) Copper(I)-bleomycin: structurally unique complex that mediates oxidative DNA strand scission. Biochemistry 24(1):81–92. doi:10.​1021/​bi00322a013 PubMedCrossRef
50.
51.
52.
53.
Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, Crysler C, Chen Y, Yurkow EJ, Boczon L, Meegalla SK, Wilson KJ, Wall MJ, Chen J, Ballentine SK, Ott H, Baumann C, Lawrence D, Tomczuk BE, Molloy CJ (2009) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumours, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8(11):3151–3161. doi:10.​1158/​1535-7163.​MCT-09-0255 PubMedCrossRef
54.
Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K, Hashimoto K, Mori H, Saji H (2007) Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 48(1):122–127PubMed
55.
56.
Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G (1998) The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 74(5):2152–2158PubMedCrossRef
57.
Puc M, Corović S, Flisar K, Petkovsek M, Nastran J, Miklavcic D (2004) Techniques of signal generation required for electropermeabilization. Survey of electropermeabilization devices. Bioelectrochemistry 64(2):113–124PubMedCrossRef
58.
Miklavčič D, Serša G, Brecelj E, Gehl J, Soden D, Bianchi G, Ruggieri P, Rossi CR, Campana LG, Jarm T (2012) Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput 50(12):1213–1225. doi:10.​1007/​s11517-012-0991-8 PubMedCrossRef
Metadata
Title
Electrochemotherapy is effective in the treatment of rat bone metastases
Authors
Milena Fini
Francesca Salamanna
Annapaola Parrilli
Lucia Martini
Matteo Cadossi
Melania Maglio
Veronica Borsari
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9601-x

Other articles of this Issue 8/2013

Clinical & Experimental Metastasis 8/2013 Go to the issue

Research Paper

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs

Research Paper

Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells

Research Paper

TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer

Research Paper

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report

Research Paper

Decreased expression and aberrant methylation of Gadd45G is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma

Research Paper

Acidic pH via NF-κB favours VEGF-C expression in human melanoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits